REG - Tristel PLC - PCA Dealing

TristelAnnouncement

Yesterday 16:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260303:nRSC1836Va&default-theme=true

RNS Number : 1836V  Tristel PLC  03 March 2026

 

Tristel plc

("Tristel" or the "Company")

 

PCA Dealing

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products,
announces that it was notified on 3 March 2026 that Glenn Stephens, a PCA of
Caroline Stephens, Non-Executive Director of the Company, purchased 2,310
ordinary shares of 1 penny each in the Company ("Ordinary Shares") at a price
of 389 pence per Ordinary Share.

 

Following the purchase, Caroline Stephens' beneficial interest in the Company,
including those held by her PCA, is 4,281 Ordinary Shares, representing
approximately 0.01 per cent. of the Company's issued share capital.

 

For further information please contact:

 

 Tristel plc                                                                   Via Walbrook PR
 Matt Sassone, Chief Executive Officer                                         www.investors.tristel.com (http://www.investors.tristel.com/)
 Anna Wasyl, Chief Financial Officer

 Walbrook PR Ltd             Tel: 020 7933 8780 or tristel@walbrookpr.com
                             (mailto:tristel@walbrookpr.com?subject=tristel@walbrookpr.com)
 Paul McManus / Lianne Applegarth / Anna Dunphy          Mob: 07980 541 893/ 07584 391 303/ 07876 741 001

 Cavendish Capital Markets Ltd                                                 Tel: 020 7220 0500
 Geoff Nash / Callum Davidson / Joe Smith (Corporate Finance)
 Sunila de Silva (Corporate Broking) / Louise Talbot (Sales)

 

About Tristel plc

 

Tristel plc is a global infection prevention company focussed on the
manufacture and supply of products using its unique proprietary chlorine
dioxide (ClO2) chemistry. The Company is a market leader in manual
decontamination of medical devices, supplying hospitals with products under
the Tristel brand, which also encompasses its sporicidal surface disinfection
range offered as a sustainable alternative to commonly used pre‑wetted
plastic wipe.

 

Tristel's head office and manufacturing facility is located in Snailwell, near
Cambridge, and operates globally employing approximately 270 people across 16
subsidiaries selling into 40+ countries. The Company targets delivering
double-digit revenue growth annually, an adjusted EBITDA margin of at least
25% and a continuing progressive year-on-year growth in dividends, underpinned
by robust cash generation.

 

The Company has been listed on the London Stock Exchange's AIM market since
2005 (AIM: TSTL).

 

For more information about Tristel's product range please visit:
https://tristel.com (https://tristel.com)

 

 

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Glenn Stephens

 2    Reason for the notification

 a)   Position/status                                              PCA of Caroline Stephens, Non-Executive Director of the Company

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Tristel plc

 b)   LEI                                                          2138009DZ4LH9CZGF662

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 1p each in Tristel plc

      Identification code

                                                                   GB00B07RVT99
 b)   Nature of the transaction                                    Purchase of Ordinary Shares

 c)   Price(s) and volume(s)

Price      Volume
                                                                   389 pence  1,540

                                                            389 pence  770

 d)   Aggregated information

      - Aggregated volume                                          2,310 Ordinary Shares of 1 penny each

      - Price                                                      389 pence

 e)   Date of the transaction                                      3 March 2026

 f)   Place of the transaction                                     London Stock Exchange (AIM)

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

 

2,310 Ordinary Shares of 1 penny each

 

389 pence

 

 

e)

 

Date of the transaction

 

3 March 2026

f)

 

Place of the transaction

 

London Stock Exchange (AIM)

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHAKNBKABKDKNK



            Copyright 2019 Regulatory News Service, all rights reserved